Title:
1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/024635
Kind Code:
A1
Abstract:
Provided are a 1,3-di-substituted ketene compound having a structure as represented by formula (I) and an application thereof. Such a type of compound primarily activates peroxisome proliferator-activated receptor (PPAR) α, and also activates PPPAδ and PPPAγ. The compound may be used to treat various diseases associated with PPAR regulation and control abnormality, such as non-alcoholic fatty liver disease, and especially in treating non-alcoholic hepatitis, and may potentially be used in the treatment of diseases comprising diabetes, obesity, fibrotic diseases, cardiovascular diseases (comprising heart failure, atherosclerosis, and so on), kidney diseases (comprising chronic kidney disease, renal failure, and so on), and brain degenerative diseases (comprising Alzheimer's disease and so on), having great application value.
Inventors:
CAI XIONG (CN)
QIAN CHANGGENG (CN)
YE CHUNQIANG (CN)
HE QIJIE (CN)
QIAN CHANGGENG (CN)
YE CHUNQIANG (CN)
HE QIJIE (CN)
Application Number:
PCT/CN2018/093760
Publication Date:
February 07, 2019
Filing Date:
June 29, 2018
Export Citation:
Assignee:
GUANGZHOU BEBETTER MEDICINE TECH CO LTD (CN)
International Classes:
C07D307/78; A61K31/381; A61P3/00; A61P3/08; C07D277/62; C07D317/46; C07D327/04
Foreign References:
| CN1688532A | 2005-10-26 | |||
| CN1930122A | 2007-03-14 |
Other References:
DATABASE CAS 22 December 2008 (2008-12-22), Database accession no. 1088216-43-6
FAN JG ET AL., J DIG DIS, vol. 12, 2011, pages 38 - 44
FRANCIS G ET AL., ANN REV PHYSIOL., vol. 65, 2003, pages 261 - 311
PAWLAK M ET AL., J HEPATOL, vol. 62, 2015, pages 720 - 733
HAN L, FUTURE CARDIOL., 5 June 2017 (2017-06-05)
ADEDAPO AA ET AL., HUM EXP TOXICOL, vol. 32, 2013, pages 323 - 331
D ORIO B, CURRALZHEIMER RES., 2017
OLEFSKY J M ET AL., TREND ENDOCRIN MET, vol. 11, 2000, pages 362 - 368
KOO JB ET AL., BMC GASTROENTEROL., vol. 17, 2017, pages 73
BAYS HE, J CLIN ENDOCRINOL METAB, 2012, pages 2889 - 97
SAHEBKAR A ET AL., EXPERT OPIN PHARMACOTHER, vol. 15, 2014, pages 493 - 503m
RATZIU ET AL., GASTROENTEROLOGY, vol. 150, 2016, pages 1147 - 1159
ROBERT S ET AL., AM HEART J, vol. 164, 2012, pages 672 - 680
CONLON D. BR, J DIABETES VASE DIS, vol. 6, 2006, pages 135 - 137
BENARDEAU A ET AL., BIOORG MED CHEM LETT., vol. 19, 2009, pages 2468 - 2473
FAN JG ET AL., J DIG DIS, vol. 12, 2011, pages 38 - 44
FRANCIS G ET AL., ANN REV PHYSIOL., vol. 65, 2003, pages 261 - 311
PAWLAK M ET AL., J HEPATOL, vol. 62, 2015, pages 720 - 733
HAN L, FUTURE CARDIOL., 5 June 2017 (2017-06-05)
ADEDAPO AA ET AL., HUM EXP TOXICOL, vol. 32, 2013, pages 323 - 331
D ORIO B, CURRALZHEIMER RES., 2017
OLEFSKY J M ET AL., TREND ENDOCRIN MET, vol. 11, 2000, pages 362 - 368
KOO JB ET AL., BMC GASTROENTEROL., vol. 17, 2017, pages 73
BAYS HE, J CLIN ENDOCRINOL METAB, 2012, pages 2889 - 97
SAHEBKAR A ET AL., EXPERT OPIN PHARMACOTHER, vol. 15, 2014, pages 493 - 503m
RATZIU ET AL., GASTROENTEROLOGY, vol. 150, 2016, pages 1147 - 1159
ROBERT S ET AL., AM HEART J, vol. 164, 2012, pages 672 - 680
CONLON D. BR, J DIABETES VASE DIS, vol. 6, 2006, pages 135 - 137
BENARDEAU A ET AL., BIOORG MED CHEM LETT., vol. 19, 2009, pages 2468 - 2473
Attorney, Agent or Firm:
ADVANCE CHINA IP LAW OFFICE (CN)
Download PDF: